Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Abstract Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yannan Zhao, Cheng Liu, Yingjian Zhang, Chengcheng Gong, Yi Li, Yizhao Xie, Bingrui Wu, Zhongyi Yang, Biyun Wang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Metastatic Breast Cancer Patients
Total Lesion Glycolysis (TLG)
Intra-tumor Heterogeneity
Heterogeneity Parameter
Metabolic Tumor Volume
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/53499fd6cb6449139ee0ba36d9607cf7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/53499fd6cb6449139ee0ba36d9607cf7

Ejemplares similares